ASCO 2014: Dr. Johanna C. Bendell gives her top picks in gastrointestinal research
FROM THE ASCO ANNUAL MEETING 2014
1. Abstract LBA3, Alan P. Venook et al.
CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC).
2. Abstract 3503, Dirk Arnold et al.
Maintenance strategy with fluoropyrimidines (FP) plus bevacizumab (Bev), Bev alone, or no treatment, following a standard combination of FP, oxaliplatin (Ox), and Bev as first-line treatment for patients with metastatic colorectal cancer (mCRC): A phase III non-inferiority trial (AIO KRK 0207).
https://abstracts.asco.org/144/AbstView_144_133066.html
3. Abstract 3504, Miriam Koopman et al.
Final results and subgroup analyses of the phase 3 CAIRO3 study: Maintenance treatment with capecitabine + bevacizumab versus observation after induction treatment with chemotherapy + bevacizumab in metastatic colorectal cancer (mCRC).
https://abstracts.asco.org/144/AbstView_144_131325.html
4. Abstract 3506, Fortunato Ciardiello et al.
Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without cetuximab.
https://abstracts.asco.org/144/AbstView_144_127862.html
5. Abstract 4005, Shuichi Hironaha et al.
RAINBOW: A global, phase III, randomized, double-blind study of ramucirumab (RAM) plus paclitaxel (PTX) versus placebo (PL) plus PTX in the treatment of metastatic gastroesophageal junction and gastric adenocarcinoma (mGC) following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy – Efficacy analysis in Japanese and Western patients.
https://abstracts.asco.org/144/AbstView_144_132412.html
6. Abstract 4000, Herbert Hurwitz et al.
RECAP: A randomized double-blind phase 2 study of ruxolitinib (RUX) or placebo (PBO) with capecitabine (CAPE) as second-line therapy in patients (pts) with metastatic pancreatic cancer (mPC).
https://abstracts.asco.org/144/AbstView_144_128761.html
Dr. Johanna C. Bendell is the director of GI cancer research and associate director of the drug development unit at the Sarah Cannon Research Institute, Nashville, Tenn.